Expert Interview
Discussing Applied Molecular Transport's AMT-101 ORAL IL-10 drug for treating pouchitis
Ticker(s): AMTIA gastroenterologist with experience in treating pouchitis
Please describe your practice as a clinician,how many patients with pouchitis do you see on a yearly basis? Can you describe the standard of care, and take us through the most promising upcoming treatments?
Could you please discuss the data from the recent FILLMORE trial?
How does AMT-101 work to treat pouchitis, and what is the mechanism of action?
Added By: slingshot_insightsCould you please talk about the evidence that supports the efficacy of AMT-101 in treating pouchitis?
How does AMT-101 compare to other treatments currently available for pouchitis?
What are the potential benefits of AMT-101 over existing treatments for pouchitis?
What are the potential risks and side effects associated with using AMT-101?
Are there any specific patient populations that would benefit more from AMT-101 than others?
Added By: slingshot_insightsHow does AMT-101 fit into the overall landscape of treatments for inflammatory bowel disease?
Are there any ongoing or planned clinical trials for AMT-101, and if so, what are the objectives of those trials?
Added By: slingshot_insightsAre there any potential competitors or alternative treatments in development that could impact the success of AMT-101?
What is your overall opinion on the potential success of AMT-101 in treating pouchitis, and how do you see it fitting into the broader landscape of inflammatory bowel disease treatments?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
